2022 Danaher Summit: Genomes to Cures
12.07.22 - 12.08.22 EDT
United States
12.07.22 - 12.08.22 EDT
United States
On December 7, 2022 in Boston, we held the first Danaher Summit, themed Genomes to Cures™.
This new annual forum for industry and academic leaders aimed to examine and debate the challenges and opportunities in the evolution of new genome-based modalities, with a call to action for specific collaborative efforts. The invitation-only event addressed a spectrum of topics related to the future of genomic medicines. World-renowned scientists, researchers and industry leaders gathered to explore key scientific innovations essential to enabling the identification, validation, manufacturing and rapid development of these advanced therapeutics.
The Summit was attended by world-leading experts in the field of genomic medicines, from Nobel-laureate researchers and top academic opinion leaders to biopharma CEOs, biotech entrepreneurs, investor groups and next-generation biomanufacturing companies. We convened these pioneers at a critical time for the biopharma and life sciences industries—a time when the emerging field of genomic medicine is radically transforming the treatment of disease as it evolves from responses to long-term remissions and cures.
Dr. Siddhartha Mukherjee M.D. DPhil, Department of Medicine, Columbia University
An overview of the past, present and future of genomic medicines and discuss the societal and ethical obligations for global democratization of these potentially curative therapies.
George Church, Ph.D.
“Convergence” involves combining technological and social innovation in ways that guide divergent, out-of-the-box ideas into daily life. Ideally, this convergence will create solutions that improve health care, while reducing costs and social inequities. The future of medicine promises to bring more convergent innovations that will revolutionize health care.
Andrew W. Lo
We’re experiencing a Golden Age of Biomedicine, but the funding and business models we use to commercialize these technologies have barely changed, making it challenging for younger scientists and entrepreneurs to bring their most innovative ideas into practice. Professor Lo describes the financial considerations that create bottlenecks in commercialization, delivery and reimbursement, as well as current and emerging solutions, including venture philanthropy, portfolio companies, securitization techniques and new payment models.
Moderated by Conor McKechnie
Panelists:
Mitchell Finer, ElevateBio
Doug Ingram, Sarepta
Eliana Clark, Intellia
Katy Rezvani, MD Anderson Cancer Center
Sonia Vallabh, Mass General Hospital, Broad Institute
This panel covers the current challenges that drug developers face in advancing potential life-saving treatments to patients, with specific focus on biomanufacturing and regulatory guidance. Panelists also discuss opportunities to change the paradigm of drug development and to implement sustainable manufacturing of genomic medicines.
Moderated by JC Gutierrez-Ramos
Panelists:
Carl June, University of Pennsylvania
George Church, Harvard Medical School
Fyodor Urnov, Innovative Genomic Institute, Berkeley University
Peter Marks, CBER at the FDA
Panelists provide their perspectives on the programs and the platforms that have the biggest potential to provide therapeutic benefits, with line of sight for smooth regulatory pathways. We discuss a future of highly personalized therapeutics, its implications, and the role and responsibilities for all involved parties—and, importantly, opportunities for new regulatory frameworks to enable this new wave of therapeutic advances.